The SoftBank-backed biological analysis technology provider priced its shares above its range and will likely close the offering at $449m.

10x Genomics, a US-based biotechnology instrument provider backed by internet and telecommunications conglomerate SoftBank, raised $390m in an initial public offering on the Nasdaq Global Select Market yesterday. The company priced 10 million shares at $39.00 each, above the IPO’s $31 to $35 range. The underwriters have the 30-day option to buy another 1.5 million…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.